- Phase II trial of 4' deoxydoxorubicin (DXDX) for unresectable non-small cell bronchogenic carcinoma. An Illinois Cancer Council study. Rose, C., Lad, T.E., Kilton, L.J., Schor, J., Rosen, S.T., Rossof, A.H., Blough, R.R., Johnson, C.M. Investigational new drugs. (1990)